SynthesisJournal of the ASEAN Federation of Endocrine Societies2026
High Remnant Cholesterol Increased the Risk of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) or Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review and Meta-Analysis.
Synthesis in Journal of the ASEAN Federation of Endocrine Societies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: MAFLD is currently acknowledged as the most common chronic liver disease and is strongly associated with obesity, metabolic dysregulation and diabetes. MAFLD is defined by the accumulation of lipids within the liver due to impaired lipid metabolism. Objective: The objective of this study is to assess the association between increased remnant cholesterol levels and the likelihood of developing MAFLD or NAFLD. Methodology: A systematic review and meta-analysis were performed in accordance with PRISMA recommendations. Databases such as the Cochrane Library and PubMed were queried for relevant material through March 21, 2025, using specific keywords related to remnant cholesterol and fatty liver disorders. The inclusion criteria concentrated on research investigating the influence of remnant cholesterol on the incidence of NAFLD/MAFLD. Data extraction and quality evaluation were conducted utilizing the JBI Critical Appraisal Checklist for Cohort Studies and ROBINS-I instruments. Results: Six studies were eventually included in our systematic review, including cross-sectional studies with a total of 45,821participants. The meta-analysis, conducted with Review Manager version 5.4, demonstrated a significant association between elevated remnant cholesterol levels and an increased risk of NAFLD/MAFLD, yielding a relative risk (RR) of 3.18 (95% CI 1.89-5.37; Conclusion: Remnant cholesterol is associated with MAFLD or NAFLD. Increased remnant cholesterol is a risk factor for MAFLD or NAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.